Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only some mechanistic/composition and general counseling statements align with the provided excerpts; however, critical label areas (contraindications, major warnings/boxed warnings if any, and use in specific populations such as pregnancy/lactation/pediatrics) are not addressed, preventing confirmation of overall on-label alignment.
Category Scores
Accurate Statements
Evotaz combines two active ingredients: atazanavir and cobicistat in a fixed-dose tablet.
Section 11 DESCRIPTION: EVOTAZ is a fixed-dose tablet containing atazanavir and cobicistat.
Evotaz is taken by mouth as a fixed-dose tablet.
Section 11 DESCRIPTION: fixed-dose tablet for oral administration.
Evotaz includes cobicistat.
Section 11 DESCRIPTION: EVOTAZ contains atazanavir and cobicistat.
Evotaz is an atazanavir/cobicistat combination.
Section 11 DESCRIPTION: EVOTAZ contains atazanavir and cobicistat.
People need to check for interactions before starting new prescriptions, over-the-counter medicines, or supplements.
Section 17 PATIENT COUNSELING INFORMATION: EVOTAZ may interact with many drugs; advise patients to report any other prescription, nonprescription medication, or herbal products.
It is important to follow the specific instructions from the prescribing information for food guidance.
Section 17 PATIENT COUNSELING INFORMATION: advise patients to take EVOTAZ with food every day.
Cobicistat boosts atazanavir by inhibiting drug-metabolizing enzymes.
Section 11 DESCRIPTION: cobicistat is a mechanism-based inhibitor of CYP enzymes of the CYP3A family; and Section 12.1 Mechanism of Action: EVOTAZ consists of atazanavir and CYP3A inhibitor cobicistat.
Cobicistat can interact with other medications, including drugs that affect metabolism in the liver.
Section 5.8 and Section 7.1/7.2: CYP3A inhibition/transporters; however the provided excerpts do not explicitly use 'liver' wording.
Unsupported Statements
HIV needs protease to mature and become infectious.
No such statement in provided label excerpts.
Evotaz is designed to maintain sufficient atazanavir exposure so it can suppress viral replication.
No such statement in provided label excerpts.
Protease inhibitor–based therapies are associated with gastrointestinal effects and lab changes.
No such class-level statement in provided label excerpts.
Other protease inhibitor regimens may use different protease inhibitors or different boosting agents.
No such statement in provided label excerpts.
Different protease inhibitors or boosting agents can change interaction risk, side effect profile, dosing convenience, and lab monitoring needs.
No such statement in provided label excerpts.
Evotaz generic or alternative availability can be checked based on patent timelines.
No such statement in provided label excerpts.
Contradictions
Important Omissions
Contraindications for EVOTAZ (Section 4), including specific prohibited coadministrations.
Importance:
High
Major warnings/boxed-warning content (if any) and key warnings and precautions statements beyond drug-interaction counseling (e.g., other specific warnings listed in labeling excerpts).
Importance:
High
Use in specific populations, including pregnancy and lactation recommendations and pediatric safety/effectiveness.
Importance:
High
Dose and administration details (e.g., dosing conditions and restrictions related to coadministration/food and any dosing recommendations), beyond a general 'take with food' counseling statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes incomplete/uncorroborated mechanistic and class-level claims and omits major label elements (contraindications; comprehensive warnings; pregnancy/pediatric/lactation guidance), which could lead to unsafe or inaccurate on-label interpretation relative to the FDA label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Critical FDA label sections (contraindications, major warnings/boxed warnings if applicable, and specific populations such as pregnancy/pediatrics/lactation) are not evaluated or reflected; several claims are unsupported or only partially supported by the provided excerpts.
Suggested Improvement
Align the response strictly to the provided label text by: (1) covering Section 4 contraindications and key coadministration restrictions; (2) addressing all major warnings/precautions from the labeling excerpts; (3) covering pregnancy/lactation/pediatric use statements; and (4) removing or rephrasing claims that are not present in the provided label excerpts (e.g., class-level protease-inhibitor effects not shown).